Table 3. Demographics of compliant vs. non-compliant patients.

Characteristic	Non-Compliant (N=70)	Compliant (N=83)	p-value
Gender			0.488
Male	62 (88.6%)	70 (84.3%)
Female	8 (11.4%)	13 (15.7%)
Age			0.699
Mean ± SD	59.6±9.9	62.4±10
Median and Range	62 (33-75)	63 (33-87)
Ethnicity			0.570
Hispanic or Latino	7 (10.3%)	6 (7.3%)
Not Hispanic or Latino	61 (89.7%)	76 (92.7%)
Race			0.708
White	47 (67.1%)	63 (75.9%)
Black	8 (11.4%)	7 (8.4%)
Hispanic	7 (10%)	6 (7.2%)
Asian	7 (10%)	7 (8.4%)
Multiple	1 (1.4%)	0 (0.0%)
Cancer Stage			0.952
1	2 (3.4%)	4 (5.8%)
2	6 (10.3%)	7 (10.1%)
3	11 (19%)	14 (20.3%)
4	39 (67.2%)	44 (63.8%)
Cancer Site
Oral	5 (7.1%)	9 (10.8%)	0.576
Nasopharynx	7 (10%)	8 (9.6%)	1
Oropharynx	35 (50%)	36 (43.4%)	0.422
Hypopharynx	5 (7.1%)	15 (18.1%)	0.055
Larynx	10 (14.3%)	10 (12%)	0.811
Other	8 (11.4%)	9 (10.8%)	1
Time since completion of radiation therapy
Mean ± SD	57.5±59.3	56.1±61.7
Median and Range	24 (4-170)	36 (3-260)
Treatments
Prior Radiation Therapy	4 (5.8%)	4 (5%)	1
Chemotherapy	49 (73.1%)	65 (81.3%)	0.321
Surgery	37 (52.9%)	38 (46.3%)	0.515
RT Modality			0.142
IMRT	29 (41.4%)	47 (56.6%)
Brachytherapy	0 (0.0%)	1 (1.2%)
Conventional	34 (48.6%)	28 (33.7%)
Stereotactic	1 (1.4%)	0 (0.0%)
Multiple modalities	6 (8.6%)	7 (8.4%)
Baseline Dysphagia Outcomes
PAS Total	5.33±1.85	5.13±1.82	0.56
PSS Total	63.20±22.13	58.67±21.03	0.25
HNCI Total	31.87±21.55	28.52±19.81	0.38
OPSE Total	41.30±22.51	39.08±19.86	0.59
Hyoid Anterior	7.59±3.64	6.39±4.01	0.12
Hyoid Posterior	18.35±9.07	15.73±8.55	0.14

Abbreviations: RT, radiotherapy; CRT, chemoradiotherapy; IMRT, intensity-modulated radiotherapy.